Research topics
Microbiome articles covering gut bacteria, microbial changes, microbiota research, and IBD disease mechanisms.
Page 6 of 12 · 570 articles
Protease and serpin activity affect the gut barrier, immunity, and microbial ecology—processes central to IBD. Integrating these pathways could help identify biomarkers or targets that explain why IBD varies between...
Preclinical results suggest a fermented yak milk–derived probiotic strain may protect against colitis in mice by improving barrier function, lowering inflammatory cytokines, and changing the gut microbiome—mechanisms...
Patients and clinicians often seek adjunctive options to improve symptoms, quality of life, or reduce treatment burden. This trial tests whether Bacillus spore probiotics added to standard care can provide measurable...
Mapping microbes and metabolites directly from different gut regions could reveal location-specific changes linked to IBD activity and help researchers develop better biomarkers or targeted treatments.
Microbial tryptophan metabolites may help restore the intestinal barrier via AhR signaling, a process that could reduce inflammation and symptom-driving permeability in IBD. Understanding this pathway could point to...
The study suggests that in some people with IBD who have Candida overgrowth, systemic antifungal therapy (fluconazole) can change gut microbes and metabolites in ways linked to better disease activity over 8 weeks. That...
This study explores genetic risk variants (NOD2/CARD15) and local environmental factors (khat use) among young adults with IBD in Djibouti — information that may help explain regional differences in Crohn’s disease and...
The study expands the map of gut archaea and identifies archaeal species associated with IBD/UC, suggesting new microbial biomarkers and potential microbe–microbe interactions that might influence inflammation.
People with UC have lower baseline gut microbial diversity and slower recovery after PEG bowel preparation; improving recovery of beneficial microbes could matter for symptom stability and gut health. This study suggests...
This preclinical study suggests that a specific gut microbe (Bacteroides acidifaciens) and the bile acid UDCA can reduce inflammation in a mouse colitis model by improving barrier function and dampening NLRP3-driven...
People with chronic colitis/IBD have higher rates of cardiovascular disease. This mouse study identifies a gut microbiota → immune cell → cardiac pathway (TLR4–GBP1) that might explain that link and point to future...
Treatment resistance is a major hurdle in IBD care; this review maps how microbiota, immune imbalance, and epigenetics may work together to cause drug-resistant disease and suggests potential precision strategies that...
Microbiome-based treatments target inflammation and microbial balance — central issues in IBD — and could offer new therapeutic options. This review collates clinical and mechanistic evidence but warns that results are...
If you or someone you care for is not responding to anti‑TNF drugs for ulcerative colitis, this review explains biological reasons why that may happen and points toward research directions that could lead to better tests...
The review presents an emerging nanotechnology (TCM-derived carbon-dot nanozymes) that could offer new multitarget anti-inflammatory and antioxidant approaches for IBD, addressing limitations of current therapies and...
Patient-derived intestinal organoids offer a human-relevant platform that could improve understanding of pediatric IBD biology and help predict individual treatment responses — potentially reducing trial-and-error...
This review highlights probiotic and synbiotic approaches centered on L. plantarum that aim to rebalance gut microbiota and support the intestinal barrier—areas of direct interest to people with IBD seeking adjunctive,...
The study provides a more rigorous, leakage-free machine-learning analysis of a major IBD microbiome cohort and proposes reproducible microbial and metabolic pathway candidates that could eventually help IBD diagnosis or...
Researchers are exploring plant-derived polyphenols as potential anti-inflammatory agents for IBD. This preclinical study suggests a Tsaoko Fructus extract reduced colitis in mice, altered the gut microbiome toward...
Preclinical work identified a plant-root extract fraction that reduced inflammation and improved some gut-barrier and microbiome features in a mouse model of ulcerative colitis, which could guide future research into new...
Improving oral delivery and colon targeting of probiotics could make probiotic therapies more effective for ulcerative colitis by increasing survival through the gut and retention at inflamed sites. If translated to...
FABP2 is presented as a sensitive biomarker of intestinal mucosal injury and a possible contributor to IBD mechanisms; if validated, it could improve disease monitoring and suggest new therapeutic targets.
Arthritis is a common and meaningful extraintestinal problem for people with IBD; understanding diagnosis and treatment options can help patients and clinicians seek appropriate multidisciplinary care.
The study identifies a new compound that reduced colitis severity in mice by acting on macrophage NF-κB signaling, lowering MMP7, improving epithelial barrier markers, and altering the gut microbiome — mechanisms...
The study suggests that polyphenols can change gut bacteria and metabolite production differently in people with IBD versus healthy controls, which could matter for designing personalized dietary interventions.
This mouse study suggests a blueberry-derived anthocyanin plus pectin complex can alter gut microbes and metabolites linked to inflammation, pointing to a dietary approach that might influence ulcerative colitis biology.
The review summarizes how extracellular vesicles (EVs) shape immune responses and barrier repair in the gut and discusses their potential as accessible biomarkers and as vehicles for precise IBD therapies — topics that...
The review proposes a low-cost, non-immunosuppressive adjunctive strategy targeting the gut microbiome and luminal metabolism to help maintain remission in UC, an area of strong patient interest but limited clinical...
This study points to a plant-derived extract delivered in nanocarriers that reduced colon injury in a rat model of colitis, suggesting a potential route to targeted anti-inflammatory therapy that might avoid systemic...
Researchers are exploring natural compounds that might reduce intestinal inflammation and rebalance the gut microbiome. If translatable to humans, such approaches could inform new treatments or adjunctive therapies for...
IBD can cause cognitive and neurological symptoms. This preclinical study suggests a flavonoid-rich Chrysanthemum extract reduced colitis and related cognitive deficits in mice by changing the gut microbiota and...
This trial tests a new oral live biotherapeutic designed to affect inflammation and the gut microbiome in Crohn’s disease. Early‑phase safety and pharmacodynamic results could influence future development of...
Understanding PTMs may help researchers identify new biomarkers or therapeutic targets for ulcerative colitis, which could eventually lead to better treatments or tests. For people with UC, this explains part of why...
Butyrate supports intestinal health and is often low in IBD. A single oral compound that reliably restores luminal butyrate could — if proven safe and effective in humans — offer a new way to treat ulcerative colitis or...
Researchers and clinicians are exploring fungi’s role in IBD beyond bacteria. For patients, seeing Candida in stool tests is usually a signal of microbiome disruption rather than proof of fungal infection that requires...
This preclinical study suggests Antarctic krill oil may reduce inflammation and alter the gut microbiome in a mouse model of ulcerative colitis, which could point toward microbiota-targeted nutritional strategies worth...
Environmental cadmium exposure may alter the gut microbiome’s metabolites (oleic acid) and worsen colitis in mice via FFAR4-linked inflammatory pathways. If similar mechanisms operate in people, this could point to new...
This study identifies conserved, gut-enriched genes (colonization factors) and shows their repertoires are remodeled in IBD, highlighting functional microbiome changes that could inform future biomarkers or...
Diet quality was linked to gut microbiome features and exploratory differences in inflammatory markers and symptoms in adults with Crohn disease from Puerto Rico; understanding these links may help tailor dietary...
Because having a sibling with Crohn's disease during childhood was linked to substantially higher risk of developing Crohn's later, and the study points to early-life microbiome differences and elevated faecal...
People with IBD might be interested because the study explores a new natural-product intervention that appears to reduce colitis severity in an animal model by activating the Nrf2 antioxidant pathway — a pathway already...
Researchers are exploring ferroptosis as a double-edged mechanism: preventing it may protect healthy gut lining in IBD, while inducing it might help treat colorectal cancer. Advances could lead to new biomarkers or...
The paper suggests gut bacteria make an anti-inflammatory metabolite (NOP) that accumulates in IBD and reduces inflammatory responses in cells and multiple mouse colitis models, pointing to a potential microbiome-derived...
The paper describes plant-derived compounds that reduced inflammation and partly corrected gut microbiome disturbances in lab and mouse models of colitis, suggesting a possible route to microbiome-targeted IBD therapies...
Fucosylation appears to influence intestinal barrier function, host–microbiota interactions, and immune responses — processes central to IBD pathogenesis. If validated, fucosylation-related biomarkers or therapies could...
The study suggests a traditional Chinese medicine formula can reduce disease signs in a mouse model of chronic relapsing ulcerative colitis and that its effects are mediated by changes in the gut microbiota and microbial...
The study reports an experimental coating that both protects a probiotic and provides antioxidant, anti-inflammatory effects in a mouse colitis model—an approach that, if validated in humans, could improve probiotic...
The study suggests a natural seaweed-derived polysaccharide could modify gut bacteria and immune signaling in ways that reduced experimental colitis, which may interest people looking for microbiota-targeted dietary...
